DASHENLIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.12 CNY | -3.24% |
|
+1.56% | -11.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 29.49B 4.08B | Sales 2025 * | 36.63B 5.06B | Capitalization | 25.19B 3.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.41B 194M | Net income 2025 * | 1.82B 252M | EV / Sales 2024 * | 0.81 x |
| Net cash position 2024 * | 1.42B 196M | Net cash position 2025 * | 1.86B 257M | EV / Sales 2025 * | 0.64 x |
| P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
13.8
x | Employees | 45,466 |
| Yield 2024 * |
1.68% | Yield 2025 * |
2.97% | Free-Float | 33.44% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.24% | ||
| 1 week | +1.56% | ||
| Current month | +1.56% | ||
| 1 month | +6.09% | ||
| 3 months | -12.67% | ||
| 6 months | -12.91% | ||
| Current year | -11.16% |
1 week
22.00
22.92
1 month
19.8322.92
Current year
19.8327.10
1 year
19.8330.22
3 years
15.9044.32
5 years
15.9061.63
10 years
11.0061.63
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Qiang Ke
CEO | Chief Executive Officer | 42 | - |
Guang Zhi Peng
DFI | Director of Finance/CFO | 42 | 18-05-09 |
Zhi Hui Chen
CHM | Chairman | 46 | 15-05-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Chang Liu
BRD | Director/Board Member | 61 | 16-08-07 |
Yun Feng Ke
FOU | Founder | 57 | 99-02-11 |
Zhi Hui Chen
CHM | Chairman | 46 | 15-05-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 4 M€ | -2.96% | ||
| 0.07% | 1 M€ | +3.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 22.12 | -3.24% | 5,909,817 |
| 24-05-09 | 22.86 | +2.97% | 8,229,858 |
| 24-05-08 | 22.2 | -0.31% | 5,058,632 |
| 24-05-07 | 22.27 | +0.18% | 6,042,283 |
End-of-day quote Shanghai S.E., May 09, 2024
More quotes
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market.
Sector
Drug Retailers
Calendar
2024-05-19
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
22.12
CNY
Average target price
33.11
CNY
Spread / Average Target
+49.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.16% | 3.49B | |
| -34.16% | 14.83B | |
| -22.25% | 12.04B | |
| -24.76% | 6.52B | |
| +14.96% | 6.44B | |
| -9.27% | 6.15B | |
| -3.50% | 4.63B | |
| +60.00% | 4.62B | |
| -8.10% | 3.93B | |
| -6.69% | 3.05B |
- Stock Market
- Equities
- 603233 Stock
